[Immunotoxins and immunocytokines].

Area of Science:

• Biotechnology and Biopharmaceutical Engineering
• Molecular and Cellular Therapeutics
• Immunology and Cancer Biology

Background:

• Cytokines and biological toxins are potent therapeutic molecules with significant limitations, including severe side effects and poor pharmacokinetics.
• These limitations have historically hindered the widespread clinical application of cytokines and toxins as standalone therapies.
• Recombinant protein engineering offers a strategy to overcome these challenges by creating novel therapeutic constructs.

Purpose of the Study:

• To review the development and clinical evaluation strategies for immunocytokines and immunotoxins.
• To explore how antibody engineering addresses the limitations of native cytokines and toxins.
• To discuss the challenges and successes in the clinical application of these biotherapeutics.

Main Methods:

• Genetic fusion of immunoglobulin components (whole antibodies, fragments, domains) with cytokines or toxins.
• Development of recombinant protein engineering techniques for creating targeted biotherapeutics.
• Clinical evaluation of immunocytokines and immunotoxins to assess safety and efficacy.

Main Results:

• Immunocytokines and immunotoxins have been successfully constructed by genetically linking antibody moieties to therapeutic payloads.
• These engineered molecules aim to enhance target specificity and improve pharmacokinetic profiles compared to native agents.
• Clinical studies are evaluating the therapeutic potential and safety of various immunocytokine and immunotoxin designs.

Conclusions:

• Immunocytokines and immunotoxins represent a promising class of biotherapeutics engineered to overcome the limitations of cytokines and toxins.
• Antibody-based targeting strategies are crucial for improving the therapeutic index of these potent biomolecules.
• Continued clinical evaluation is essential to fully realize the potential of immunocytokines and immunotoxins in medicine.